Trump Places Glyphosate Under the Defense Production Act, Turning Bayer from a Corporation into a “National Asset”

On February 18, 2026, President Donald Trump signed an executive order invoking the Defense Production Act, a Cold War-era law historically reserved for safeguarding materials essential to national security. This time, however, the law was applied to an unexpected target: elemental phosphorus and glyphosate-based herbicides. With a single signature, a chemical long associated with agriculture was formally elevated into the realm of national strategic protection.

The Defense Production Act grants the federal government authority to prioritize domestic production, allocate critical resources, and provide legal protections to manufacturers deemed essential to national interests. Under the order, the Secretary of Agriculture was authorized to coordinate nationwide production priorities and ensure the continuity of glyphosate and phosphorus supply chains. The directive also explicitly required that implementation must not compromise the corporate viability of domestic producers. This language makes clear that the objective was not merely regulatory oversight, but the preservation of industrial capacity itself.

This intervention cannot be understood without recognizing a structural reality within the United States. Bayer, through its subsidiary Monsanto, operates the only fully integrated domestic glyphosate production chain. From phosphate mining in Idaho’s Soda Springs, to active ingredient synthesis in Muscatine, Iowa, and formulation in Luling, Louisiana, Bayer controls every stage of domestic production. There is no alternative U.S.-based producer capable of replacing this supply chain.

At the same time, the United States remains heavily dependent on imports to meet its total glyphosate demand. Over the past two decades, global production has shifted decisively toward China, which now accounts for more than seventy percent of global glyphosate manufacturing capacity. Chinese producers benefit from economies of scale, lower input costs, and a diversified industrial ecosystem. By contrast, domestic production in the United States operates at higher cost and lower scale. 

This imbalance exposes a fundamental vulnerability. The United States retains technological capability but lacks cost competitiveness, while China maintains cost leadership but remains outside U.S. strategic control.

In this context, the Defense Production Act order represents a strategic safeguard rather than an agricultural policy measure. It signals the federal government’s willingness to intervene directly to prevent the erosion or loss of domestic production capacity.

Bayer’s position in recent years has made such intervention increasingly urgent. Since acquiring Monsanto in 2018, the company has faced an escalating wave of glyphosate-related litigation. Tens of thousands of lawsuits remain unresolved, creating substantial legal and financial risk. Company leadership has openly described this litigation environment as a potential existential threat to its glyphosate business.

Simultaneously, upstream raw material constraints have intensified uncertainty. Phosphate mining projects critical to sustaining long-term production have faced regulatory delays and legal challenges. Without secure upstream supply, even existing production infrastructure could face disruption.

The executive order therefore serves a dual function. In the short term, it stabilizes domestic production by reducing regulatory and legal uncertainty. In the long term, it reinforces a policy framework aimed at preserving strategic autonomy over essential chemical supply chains.

This intervention also carries global implications. Glyphosate is not merely a domestic agricultural input but a globally traded commodity. Any policy that alters production incentives or supply chain resilience within the United States inevitably affects international market dynamics.

However, the order does not immediately eliminate U.S. dependence on imports. Domestic production capacity cannot fully satisfy national demand, and developing new upstream mining and manufacturing capacity requires years of investment and regulatory approval. In the interim, imported glyphosate—particularly from China—remains indispensable.

Moreover, structural pressures within the glyphosate industry persist. The spread of herbicide-resistant weeds continues to increase reliance on chemical weed control, while regulatory scrutiny and public concern remain elevated. These opposing forces create a complex environment in which supply security and political sensitivity coexist.

Bayer itself appears to recognize the long-term uncertainty. The company has accelerated development of next-generation herbicides through its CropKey platform, including icafolin-methyl. This diversification strategy reflects an understanding that even with government support, reliance on a single legacy product carries strategic risk.

Viewed in a broader context, Trump’s decision reflects a fundamental shift in how industrial policy is being applied. For decades, globalization allowed production to concentrate in regions offering the lowest cost. Today, supply chain resilience has become an equally critical objective. Governments are increasingly prioritizing control over strategic production capacity, even at higher economic cost.

By invoking the Defense Production Act, the United States has formally declared that glyphosate and its upstream raw materials are no longer merely commercial goods, but strategic assets.

This designation changes the nature of competition within the global agrochemical industry. Production decisions will no longer be shaped solely by market economics but increasingly by policy, legal frameworks, and geopolitical considerations.

Glyphosate remains a herbicide. But its significance has evolved beyond agriculture. It now represents a critical node in the intersection of industrial capability, supply chain resilience, and national strategy.